Home >> Lifestyle

Drug combo found to halt tumour growth in aggressive lung cancer

Researchers at Mayo Clinic in Florida, US, have been able to shut down one of the most lethal forms of lung cancer by administering a combination of rheumatoid arthritis drug auranofin and an experimental targeted agent.

The combination therapy worked in a lab study to stop lung adenocarcinoma associated with mutation of the KRAS gene.

Senior author Alan Fields said the combination therapy might work in other KRAS-mediated cancers, such as colon and pancreatic cancers, as well as other cancer types.

It was found that the combination therapy shuts down a major signaling pathway, or set of molecular mechanisms, that stimulates the growth of cancer stem cells in KRAS-mediated lung adenocarcinoma.

The study has been published in the journal Cancer Cell.